Patent · US Active

Spirocyclic degronimers for target protein degradation

US10660968B2 · kind B2 · utility

23Cited by

7References

35Claims

0Family size

Assignee

C4 THERAPEUTICS, INC.

Inventors

Andrew J. Phillips · Arlington, US
Chris G. Nasveschuk · Stoneham, US
James A. Henderson · Cambridge, US
Yanke Liang · Belmont, US
Kiel Lazarski · Cambridge, US
Ryan E. Michael · Newton, US

Key dates

Filing date	Nov 9, 2018
Grant date	May 26, 2020
Priority date	—
Expiry date	Nov 9, 2038

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

This invention provides compounds that have spirocyclic E3 Ubiquitin Ligase targeting moieties (Degrons), which can be used as is or linked to a targeting ligand for a protein that has been selected for in vivo degradation, and methods of use and compositions thereof as well as methods for their preparation.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.